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ab
stract
PURPOSE High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments
include intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC). We wanted to
understand whether a randomized trial comparing these options was possible.
MATERIALS AND METHODS We conducted a two-arm, prospective multicenter randomized study to determine
the feasibility in Bacillus Calmette-Guerin-naive patients. Participants had new high-risk HRNMIBC suitable for
both treatments. Random assignment was stratified by age, sex, center, stage, presence of carcinoma in situ,
and prior low-risk bladder cancer. Qualitative work investigated how tomaintain equipoise. The primary outcome
was the number of patients screened, eligible, recruited, and randomly assigned.
RESULTS We screened 407 patients, approached 185, and obtained consent from 51 (27.6%) patients.
Of these, one did not proceed and therefore 50 were randomly assigned (1:1). In the mBCG arm, 23/25 (92.0%)
patients received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after induction, three had
NMIBC at 4 months, and four received RC. At closure, two patients had metastatic BC. In the RC arm,
20 (80.0%) participants received cystectomy, including five (25.0%) with no tumor, 13 (65.0%) with HRNMIBC,
and two (10.0%) with muscle invasion in their specimen. At follow-up, all patients in the RC arm were free of
disease. Adverse events were mostly mild and equally distributed (15/23 [65.2%] patients with mBCG and
13/20 [65.0%] patients with RC). The quality of life (QOL) of both arms was broadly similar at 12 months.
CONCLUSION A randomized controlled trial comparing mBCG and RC will be challenging to recruit into.
Around 10% of patients with high-risk HRNMIBC have a lethal disease and may be better treated by primary
radical treatment. Conversely, many are suitable for bladder preservation and may maintain their pre-
diagnosis QOL.
J Clin Oncol 00. © 2020 by American Society of Clinical Oncology
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INTRODUCTION
Bladder cancer (BC) is a common malignancy and
one of the most expensive to manage.1,2 Around 25%
of patients present with high-grade nonmuscle in-
vasive (NMI) tumors. Rates of progression to muscle
invasion vary between 15% and 50%.3 Around 20% of
patients may die from BC.4 Progression risks increase
with carcinoma in situ (CIS), invasion into the lamina
propria, or prostatic urethral involvement. Conse-
quently, these features can be used to identify high-
risk high-grade NMIBC (HRNMIBC).3
The treatment options for HRNMIBC are intravesical im-
munotherapy (using maintenance intravesicalBacillus
Calmette-Guerin [mBCG]) and radical cystectomy
(RC).5,6 Although mBCG avoids bladder removal, it
leaves patients at risk of progression and may affect
health-related quality of life (HRQOL) through local
symptoms and anxiety.7 RC removes the risk of local
disease progression, but maybe overtreatment for non-
progressing tumors. Many patients develop postop-
erative complications after RC, around 3% die after
90 days,8 and others have a reduction in HRQOL.9,10
RC and mBCG have not been directly compared,
hampering decision making and exposing patients
to overtreatment or undertreatment.11 As RCTs com-
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challenging to complete,12,13 we undertook a feasibility
study to assess whether recruitment was possible. We
embedded qualitative components exploring patient ex-
perience and clinician equipoise. We hypothesized that
recruitment and random assignment would not be possible.
MATERIALS AND METHODS
Patients and Random Assignment
BRAVO was a multicenter, parallel-group, mixed-methods,
individually randomized, controlled feasibility study14 run
through seven NHS cancer networks. Eligible patients were
$ 18 years old with a new diagnosis of high-grade15 or
grade 316 NMI urothelial cell carcinoma (UCC) (either pTa,
pTis, or pT1). One or more criteria from presence of pTis,
lympho(vascular) invasion, residual grade 3/high UCC
on re-resection, multifocal disease (. 3 tumors), young
age (, 65 years old), initial tumor size . 3 cm (or . 5 g
in histology specimen), or pT1 stage were also needed.
Participants were consented by clinicians and randomly
assigned (1:1) by the Clinical Trials Research Unit. Random
assignment was stratified by age (, 75, $ 75), sex, center,
highest transurethral resection of bladder tumor stage (pTa/
pTis, pT1), the presence of CIS, and previous low-risk BC. Re-
resection was performed if the transurethral resection of
bladder tumor specimen had T1 disease or Ta/Tis disease
without detrusor muscle.17 It was not possible to blind treat-
ment allocation. The study has ethical approval (16/YH/0268).
Treatment and Follow-Up
Successful mBCG was defined as$ 4 induction doses and
at least 12 months of maintenance treatment using the
SWOG protocol.18 mBCG could continue in the presence
of HRNMIBC at first cystoscopy after induction of Bacillus
Calmette-Guerin (BCG) or in the presence of low-risk non-
muscle invasive bladder cancer (NMIBC) at any time.
The presence of HRNMIBC or invasive BC after induction
required the cessation of mBCG. Rigid cystoscopy with
biopsy and bladder washings or urine cytology was
mandated at the first check. Thereafter, cystoscopic ap-
proach was per local protocol. Dose adjustment for BCG
was not permissible. Please see our methods report14 and
protocol (Data Supplement, online only) for more details.
RC included removal of the prostate or seminal vesicles in
men, and uterus or cervix or fallopian tubes and anterior
vaginal wall in women. Pelvic lymphadenectomy included,
at least, regional lymph nodes up to the ureteric crossing of
the common iliac vessels. To minimize surgical variation,19
only surgeons with $ 10 years’ RC experience or reported
(British Association of Urological Surgeons data set20) out-
come data on$ 10 RCs per year for the last 2 years (or 20 in
the last year), with amedian length of stay under 16 days and
a 90-day post-RC mortality rate of , 10%, were used.
Follow-up included three monthly clinic review and chest or
abdominal or pelvis computed tomography scans 52 weeks
after random assignment. HRQOL questionnaires were
administered prior to random assignment and at 3 and
6 months after random assignment. For those randomly
assigned early to the study, HRQOL results were collected
at 12 months after random assignment. Measures included
EuroQuol-5D (EQ-5D),21 EORTC QLQ-C30,22 and either
EORTC QLQ-BLM30 (RC cohort) or EORTC QLQ-NMIBC24
(for BCG). Decision regret questionnaires asking about
trial participation and acceptance of allocated treatments
were completed at 12 months. Deaths, complications, and
toxicities (adverse events [AEs]), and related unexpected
serious AEs up to 12 months after random assignment, or
3 months after the last participant was randomly assigned
were collected. Please see Ref. 14 and the protocol (Data
Supplement).
Outcomes
Primary outcomes were the number of patients screened,
eligible, recruited, and randomly assigned in the study.
Secondary outcomes included the acceptance rates of allo-
cated treatments, 12-month mBCG compliance, feasibility
of collecting (including optimal schedule and likely
CONTEXT
Key Objective
We wanted to understand whether a randomized trial comparing intravesical maintenance Bacillus Calmette-Guerin
(mBCG) and radical cystectomy (RC) for high-grade nonmuscle invasive bladder cancer (HRNMIBC) was possible.
Knowledge Generated
An RCT comparing mBCG and RC will be difficult to conduct. In the mBCG arm, 23/25 (92.0%) patients received mBCG,
four had nonmuscle invasive bladder cancer (NMIBC) after induction, three had NMIBC at 4 months, four received RC,
and two developed metastases. In the RC arm, 20/25 (80.0%) participants received cystectomy, including five (25.0%)
with no tumor, 13 (65.0%) with HRNMIBC, and two (10.0%) with muscle invasion in their specimen. All patients in the
RC arm were free of disease at closure.
Relevance
Around 10% of patients with new high-risk HRNMIBC have a lethal disease and may be better treated by primary radical
treatment. Conversely, many are suitable for bladder preservation and may maintain their prediagnosis quality of life.
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distribution of) HRQOL data, and to explore the reasons
expressed by patients for declining recruitment.
Sample Size
Sample size was set to give confidence that recruitment for
a definitive trial could be met. A formal power calculation
was not appropriate. The primary end point of a phase III
trial would be cancer-specific survival. We estimated that
506 participants would be required to have 80% power
to show a superiority hazard ratio of 0.626 (based on im-
provement in 5-year cancer-specific survival from 0.7 with
mBCG to 0.8 for RC), assuming a 3-year accrual period,
5 years of follow-up, and accounting for 5% loss to
follow-up. For this feasibility study, pilot data suggested a
pool of 200 eligible patients per year, of which we estimated
we would need to randomly assign approximately 25% to
meet the rate required in a definitive trial. Thus, we aimed
to recruit a minimum of 60 participants from seven cen-
ters (and their associated district general hospitals) over
an 18-month period. This assumed a 6-month setup (re-
cruitment rate approximately four patients per center per
year) and a rate of approximately 11 patients per center per
year thereafter.
Analyses
Quantitative analyses focused on descriptive statistics and
CI estimation and were conducted on the intention-to-treat
population; formal hypothesis testing was not undertaken.
Summary statistics were calculated for screening, eligibility,
recruitment, and random assignment to provide estimates
for the definitive trial. To understand acceptability of the
study, uptake of allocated treatment and compliance with
12-month mBCG were summarized descriptively. Follow-
up rates for self-reported outcomes were reported together
with 95% CIs to understand the feasibility of collecting
quality of life (QOL) data and to inform the sample size
calculation for a definitive trial.
Qualitative Interviews
Qualitative analyses were conducted from interviews with
eight doctors, six nurse specialists, and 29 patients (14 had
received RC and 15 BCG). A manuscript summariz-
ing these results is in preparation (M. Twiddy, personal
communication, January 2020).
RESULTS
Screened, Eligible, and Randomly Assigned Populations
In total, 407 patients were screened and 215 (52.8%)
patients were found eligible (Fig 1, Data Supplement)
between October 2016 and March 2018. The commonest
reasons for ineligibility were prior HRNMIBC and/or BCG,
NMIBC lacking additional risk factors, another malignancy,
or the patient was unsuitable for both treatments. Inves-
tigators approached 185/215 eligible patients and 51
agreed to be randomly assigned (27.6%). Patients declined
random assignment because of one or more of the fol-
lowing: mBCG preference (77 [50.0%]), RC preference
(39 [25.3%]), dislike of random assignment (27 [17.5%]),
concerns about study participation (8 [5.2%]), or did not
specify (3 [1.9%]). One participant did not proceed to
random assignment (and chose mBCG outside of the
study). Consequently, 25 patients were randomly assigned
to mBCG and 25 to RC. Recruitment was halted after
18 months (as per statistical plan). The randomly assigned
cohort were typical for BC patients: most were men (4:1
ratio), between the age of 60-80 years (82.0%), and with a
smoking history (74.0%, Table 1 and Data Supplement).
Maintenance BCG
Follow-up concluded in July 2018. In the mBCG arm, 2/25
(8% of randomly assigned) participants did not commence
treatment and 23/25 (92.0% of randomly assigned) started
BCG, all within 4 weeks of random assignment (Table 2).
Of these, 22 (95.7%) participants received all induction doses
and 1 had 2 omissions because of a urinary infection or BCG-
itis before refusing further BCG (Data Supplement). All 18
who received cycle 2 and 5/6 (83.3%) participants reaching
cycle 3 received three instillations. Cycle commencement was
delayed in 14/18 (77.8%) and 3/6 (50.0%) participants for
cycle 2 and 3, respectively. In cycle 3, one patient had three
omissions because of BCG-related toxicities and feeling too
unwell for treatment. Cystoscopy during induction (ie, after 6
BCG instillations) revealed low-grade (2/22 [9.1%]) and high-
grade (2/22 [9.1%)] NMIBC in four patients. At 4 months,
low-grade pTa and high-grade pT1 NMIBC were present in
one and two patients, respectively. At follow-up, 1/25 (4.0%)
patient had progressed to distant metastatic UCC (at
12 months after random assignment), 4/25 (16.0%) patients
had receivedRC (two because of initial preference for RC, one
because of ineffectiveness of BCG post-induction (6 months
after random assignment: RC histology was pT3 N1 UCC),
and one for CIS (at 12 months after random assignment),
and one patient was receiving hyperthermic mitomycin C for
BCG-unresponsive CIS (9 months after random assignment).
Fifty-one AEs were seen in 15/23 (65.2%) patients. The
average number of AEs per person was 2.6 (standard devi-
ation [SD] 5 0.96) and 1.9 (SD 5 0.64) for induction and
cycle 2, respectively; one patient experienced twoAEs at cycle
3. Most AEs were mild (grade 1 or 2), such as urinary fre-
quency (15/51; 29.4%) or dysuria (13/51; 25.5%). However,
2 AEs were grade 3 during induction and AEs led to un-
planned hospital admission in 3/13 (23.1%) patients during
induction and in 1/8 (12.5%) patient during cycle 2 (0 in
cycle 3). In total, of thosewho commencedBCG treatment, 5
(21.7%) permanently discontinued BCG.
Radical Cystectomy
In the RC arm, 20/25 (80%) patients received primary surgery
(Table 3; including 18 within 8 weeks of random assignment
and onewho deferred RC until after coronary angioplasty) and
five (20.0%) chose mBCG. Most surgery was via an open
Journal of Clinical Oncology 3
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Not approached: 30 (14.0% of considered)
   12 Incomplete counselling
     7 Clinical decision to treat with nontrial treatment
     5 Clinician choice
     4 Failure to attend BRAVO clinic appointment
     4 Patient has treatment preference
     2 Patient does not want treatment
     1 Disease ineligible
Categories are not mutually exclusive
Not randomly assigned: 1 (2.0% of consented)
   1 Patient changed their mind due to mBCG










Consented: 51 (27.6% of
approached, 12.5% of
screened)
Randomly assigned: 50 (98.0%
of consented, 12.3% of
screened)
Not considered: 192 (47.2% of screened)
   187 Patient ineligible
       5 Clinician choice
       2 Patient has treatment preference
       3 Other
Categories are not mutually exclusive
Did not consent: 134 (72.4% of approached)
   77 mBCG preference
   39 RC preference
   27 Dislike of random assignment
     8 Concerns about participation
     3 Reason not specified
Categories are not mutually exclusive
Received mBCG: 23 (92.0%




  17 Complete
    1 Withdrawal*
    7 Missing questionnaires
6-month QoL follow-up
  18 Complete
    3 Not due
    3 Missing questionnaires
12-month QoL follow-up
  14 Complete
    8 Not due
    2 Missing questionnaires
25 included in intention-to-treat analysis25 included in intention-to-treat analysis
Received RC: 20 (80.0%
of randomly assigned to RC)
Randomly assigned to RC: 25
(50.0% of randomly assigned)
Randomly assigned to mBCG: 25
(50.0% of randomly assigned)
3-month QoL follow-up:
  22 Complete
    1 Withdrawal*
    2 Missing questionnaires
6-month QoL follow-up
  19 Complete
    4 Not due
    1 Missing questionnaires
12-month QoL follow-up
  16 Complete
    7 Not due








FIG 1. Consort diagram for the BRAVO feasibility study. mBCG, maintenance Bacillus Calmette-Guerin; QOL, quality of life; RC, radical
cystectomy.
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TABLE 1. Baseline Characteristics of the Randomly Assigned Participants
Category RC mBCG Total
Total 25 (100%) 25 (100%) 50 (100%)
Age category
, 75 18 (72.0%) 18 (72.0%) 36 (72.0%)
$ 75 7 (28.0%) 7 (28.0%) 14 (28.0%)
Sex
Male 19 (76.0%) 22 (88.0%) 41 (82.0%)
Female 6 (24.0%) 3 (12.0%) 9 (18.0%)
Diagnostic procedure
Initial TURBT 13 (52.0%) 11 (44.0%) 24 (48.0%)
Re-resection 11 (44.0%) 13 (52.0%) 24 (48.0%)
Missing 1 (4.0%) 1 (4.0%) 2 (4.0%)
Tumor stage after first TURBT
pTa 12 (48.0%) 15 (60.0%) 27 (54.0%)
pTis 3 (12.0%) 3 (12.0%) 6 (12.0%)
pT1 10 (40.0%) 7 (28.0%) 17 (34.0%)
Tumor stage after re-resection
pTa 7 (28.0%) 5 (20.0%) 12 (24.0%)
pTis 4 (16.0%) 6 (24.0%) 10 (20.0%)
pT1 7 (28.0%) 9 (36.0%) 16 (32.0%)
No re-resection 6 (24.0%) 5 (20.0%) 11 (22.0%)
Missing 1 (4.0%) 0 (0.0%) 1 (2.0%)
Diagnosed with CIS
Yes 14 (56.0%) 17 (68.0%) 31 (62.0%)
No 11 (44.0%) 8 (32.0%) 19 (38.0%)
Previous low-risk BC
Yes 2 (8.0%) 1 (4.0%) 3 (6.0%)
No 23 (92.0%) 24 (96.0%) 47 (94.0%)
Smoking status
Never smoked 5 (20.0%) 7 (28.0%) 12 (24.0%)
Ex-smoker 10 (40.0%) 11 (44.0%) 21 (42.0%)
Current cigarette smoker 10 (40.0%) 6 (24.0%) 16 (32.0%)
Missing 0 (0.0%) 1 (4.0%) 1 (2.0%)
Does participant work in industries
with bladder carcinogens?a
Yes 23 (92.0%) 19 (76.0%) 42 (84.0%)
No 2 (8.0%) 4 (16.0%) 6 (12.0%)
Missing 0 (0.0%) 2 (8.0%) 2 (4.0%)
WHO PS statusb
0 22 (88.0%) 20 (80.0%) 42 (84.0%)
1 2 (8.0%) 4 (16.0%) 6 (12.0%)
2 1 (4.0%) 1 (4.0%) 2 (4.0%)
3 0 (0.0%) 0 (0.0%) 0 (0.0%)
4 0 (0.0%) 0 (0.0%) 0 (0.0%)
(continued on following page)
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approach (17/20 [85.0%]) using an ileal conduit for urinary
drainage (17/20 [85.0%]). One case included synchronous
urethrectomy. One patient required blood transfusion (5.0%)
and one required radiological guided drain insertion for a
pelvic collection (Clavien-Dindo grade 3a: 5.0%). Five
(25.0%) participants experienced five AEs relating to cys-
tectomy (Data Supplement hemorrhage or bleeding [two],
small bowel injury [one], nerve injury [one], and difficult
dissection [one]). Six (30.0%) participants experienced 9
postoperative complications (chest infection [three], wound
infection [one], ileus [three] urine leak [one], and constipation
[one]), and consequently, 4/20 (20.0%) participants had an
increased length of hospital stay. There were no deaths within
the follow-up period. By 6 weeks after surgery, nine patients
had developed a complication (anastomotic leak [one],
constipation [three], fever [two] and sepsis [three], ileus [one],
and wound [one] or urinary infection [one]), 3 patients had a
prolonged length of stay, and 4 patients required readmission.
By 20 weeks, a further five complications (in three patients)
were observed (abdominal pain [one], fever [one], sepsis
[two], and low B12 and folate [one]). No further complications
were observed by week 52. Overall, complications were seen
in 13/20 (65.0%) participants, of which two were Clavien-
Dindo grade 3a, one grade 3b, and one grade 4a. Histology
revealed high-grade urothelial carcinoma in 15/20 patients
(Table 3, 75.0%), including muscle invasion in 2/20 (pT2N0
in 10.0%) and NMIBC in 13 (pT1 in three, pTis in eight, and
pTa in two). No tumor was found in five cases. Lymphade-
nectomy was performed in 19/20 patients, with a median of
10 nodes (range, 4-27) identified by histopathology. No nodal
metastases were detected. Four patients had UCC at the
urethral (three) or ureteric (one) resection margins. Prostate
cancer was present in five men (pT2 in three and pT3 in two,
Table 3), excluding one who had undergone prior radical
prostatectomy. Of the 10 patients with 52-week follow-up,
nine were disease-free without hydronephrosis and data for
one patient were missing. The median eGFR at 52 weeks
was 72.0 mL/min.
HRQOL Data
HRQOL questionnaires were completed in 98.0%, 78.0%,
74.0%, and 60.0% at baseline, 3, 6, and 12 months, re-
spectively. Although powered comparative analyses of
HRQOL are not possible and the EORTC Bladder tools
are not directly comparable, global trends were apparent
(Figs 2 and 3). In general, few changes in EQ-5D-3L were
seen (Data Supplement). Within QLQ-C30 functional do-
mains (Data Supplement), the RC cohort had a reduction
in QOL at 3 months, which recovered to baseline between
6 and 12 months. Little change was seen with mBCG
cohort over 12 months. Similarly, few changes were seen in
the QLQ-C30 symptom scores in both arms. Changes were
seen in treatment-specific questionnaires (Data Supple-
ment, Fig 3). For mBCG, there were small increases in the
urinary symptom scores at 6 months and concerns about
contaminating a partner at 3 months (although this reduced
by 12 months), and small reductions in future worry scores
on the NMIBC24 questionnaire with time. For the RC cohort,
most symptoms improved (lower scores) from 3 to
12 months, except sexual function, which did not change.
Decision regret questionnaires were completed by 39/50
(78.0%) participants at 12 months (Data Supplement).
There was little regret at entering the study; “It was the right
decision” (mean5 13.5, SD5 18.3, lower scores indicating
less regret) and “I would go for the same choice if I had to do
it over again” (mean 11.5, SD 5 17.3, lower scores indi-
cating less regret). With respect to individual treatments,
patients in the BCG arm had a higher regret score; “I regret
the choice that was made” (mean 5 22.1, SD 5 15.6 v
mean 5 13.2, SD 5 27.8), compared with the RC cohort.
Feasibility of Conducting a Phase III RCT
We randomly assigned 50 of the planned 60 patients within
the 18-month window. However, 47/50 (94.0%) patients were
from a single network (22 from the cancer center and 25 from
the neighboring community hospitals). Four of the seven
cancer networks did not randomly assign a patient during
TABLE 1. Baseline Characteristics of the Randomly Assigned Participants (continued)
Category RC mBCG Total
Diagnostic setting
Cancer center 9 (36.0%) 14 (56.0%) 23 (46.0%)
District hospital 16 (64.0%) 11 (44.0%) 27 (54.0%)
Serum eGFR
Mean (SD) 78.2 (14.66) 73.8 (14.71) 76.1 (14.70)
Median (range) 83.0 (40.0-104.0) 77.5 (33.0-90.0) 80.0 (33.0-104.0)
Missing 0 1 1
Abbreviations: BC, bladder cancer; CIS, carcinoma in situ; eGFR, estimated Glomerular Filtration Rate; mBCG,maintenanceBacillus Calmette-Guerin; PS,
performance status; RC, radical cystectomy; SD, standard deviation, TURBT, transurethral resection of bladder tumor.
aSee Refs. 29,30 for more details of classification of bladder carcinogens.
bWHO performance status: 0: fully active, 1: cannot undertake strenuous activity, but can carry out day-to-day tasks, 2: ambulatory and mobile for more
than 50% of waking hours, 3: confined to bed or chair for more than 50% of waking hours, 4: disabled/confined to bed or chair.
6 © 2020 by American Society of Clinical Oncology
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recruitment. Of those recruited, seven did not accept their
allocated treatments (compliance 86.0%); two of these
also withdrew from further data collection and completion
of questionnaires. A further participant withdrew from trial
treatment 121 days after random assignment.
DISCUSSION
We report the first prospective randomized comparison
of mBCG and RC. We suspected challenging recruitment
and so undertook this feasibility study.7,23 We ran train-
ing sessions using mock patient consultations, lectures










Did the participant receive BCG?
Yes 23 (92.0%) 23 (92.0%) 18 (100%) 6 (100%)
No 2 (8.0%) 2 (8.0%) 0 (0.0%) 0 (0.0%)
Did BCG administration take place within the time
frame specified in the protocol?
Yes 23 (100.0%) 4 (22.2%) 2 (33.3%)
No 0 (0.0%) 14 (77.8%) 3 (50.0%)
Missing 0 (0.0%) 0 (0.0%) 1 (16.7%)
Cytology findings
Normal 18 (78.3%) 15 (83.3%) 5 (83.3.0%)
Equivocal 1 (4.3%) 0 (0.0%) 0 (0.0%)
Suspicious for high-grade UCC 1 (4.3%) 0 (0.0%) 0 (0.0%)
Urothelial carcinoma 1 (4.3%) 0 (0.0%) 0 (0.0%)
Missing or no cystoscopy 2 (8.7%) 3 (16.7%) 1 (16.7%)
Pathology results—grade
No tumor 18 (78.3%) 13 (72.2%) 5 (83.3%)
Low grade or grade 1 or 2 2 (8.7%) 1 (5.6%) 0 (0.0%)
High grade or grade 3 or 2 2 (8.7%) 2 (11.1%) 0 (0.0%)
Missing or no cystoscopy 1 (4.3%) 2 (11.1%) 1 (16.7%)
Pathology results—stage
pTa, pTis, pT1 4 (17.4%) 3 (16.7%) 0 (0.0%)
pT2 or greater 0 (0.0%) 0 (0.0%) 0 (0.0%)
No tumor 18 (78.3%) 13 (56.5%) 5 (100.0%)
Missing or no cystoscopy 1 (4.3%) 2 (11.1%) 1 (16.7%)
Did the participant permanently discontinue BCG
(of those who received it)?
Yes 5 (21.7%)
No 18 (78.3%)
Reasons for permanently discontinuing BCG treatment
BCG toxicity or intolerance 2 (40.0%)
Local recurrence or local progression 2 (40.0%)
Other 1 (20.0%)




Normal upper tracts 6 (75%)
Hydronephrosis 2 (25%)
Abbreviations: BCG, Bacillus Calmette-Guerin; CT, computed tomography; UCC, urothelial cell carcinoma.
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TABLE 3. Treatment Compliance and Events in the RC Arm
Category Total (Percentage)
Did the participant receive RC?
Yes 20 (80.0%)
No 5 (20.0%)





Mean (SD) 26.6 (3.51)
Median (range) 26.7 (21.0-35.0)
Serum eGFR
Mean (SD) 76.7 (13.15)
Median (range) 80.0 (43.0-90.0)
Serum creatinine
Mean (SD) 82.9 (18.63)






Level I (obturator fossa) 0 (0.0%)
Level II (ureteric crossing common iliac
artery)
19 (95.0%)




Duration of operation, hours
, 3 6 (30.0%)
3-5 11 (55.0%)
. 5 3 (15.0%)
Diversion procedure
Ileal conduit 17 (85.0%)
Orthotopic 3 (15.0%)
Rectal diversion 0 (0.0%)
Continent cutaneous 0 (0.0%)
Other 0 (0.0%)
Blood loss, mL
, 300 4 (20.0%)
300-500 6 (30.0%)
. 500-1,000 7 (35.0%)
. 1,000-2,000 3 (15.0%)
. 2,000 0 (0.0%)
(continued in next column)
TABLE 3. Treatment Compliance and Events in the RC Arm
(continued)
Category Total (Percentage)
Number of blood units transfused
Nil 19 (95.0%)
Minor (, 2 units) 1 (5.0%)
Moderate (3-6 units) 0 (0.0%)








No cancer 5 (25.0%)
Low grade or grade 1 or 2 0 (0.0%)






pT2 or above 2 (10.0%)
Margins
Clear 16 (80%)
Soft tissue 0 (0.0%)
Urethral UCC 3 (15.0%)
Ureteric UCC 1 (5.0%)
Lymph nodes
, 5 2 (10.0%)
5-9 4 (20.0%)
$ 10 14 (70.0%)
Coexisting prostate cancerb
Not presentc 10 (66.7%)
Gleason grade group 1 3 (20%)
Gleason grade group 2 1 (6.7%)
Gleason grade group 3 1 (6.7%)
Coexisting prostate cancer stage
pT2 3 (60.0%)
pT3 2 (40.0%)




(continued on following page)
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challenging beliefs, and focusing upon equipoise. Many
HRNMIBCs are diagnosed in district hospitals, before
onward referral to the nearest cancer center. Patients meet
multiple clinical staff before deciding treatment, each of
whommight influence choice. Recruitment was successful
in one network, which accounted for 47/50 randomly as-
signed patients. Half of these were diagnosed at district
hospitals, suggesting clinicians in this network were in equi-
poise. Other networks struggled to recruit, suggesting either
a lack of equipoise, enthusiasm, or logistical difficulties.
Evidence to understand this may be derived from the
screening logs. These reported few patients expressed treat-
ment preference at diagnosis (1.0% in Data Supplement),




Normal upper tracts 9 (100.0%)
Hydronephrosis 0 (0.0%)
Abbreviations: BMI, body mass index; CT, computed tomography;
RC, radical cystectomy; SD, standard deviation; UCC, urothelial cell
carcinoma.
aPercutaneous drain insertion.
b15/20 participants who received an RC were male.


























































































































































































































































































































FIG 2. Generic health-related quality of life for patients in the BRAVO feasibility study as measured using the
EuroQuol-5D (EQ5D) and EORTC QLQ-C30 questionnaires. The EORTC-QLQ-C30 scores and the EQ-5D-3L
Health score today range from 0 to 100, with high scores indicating better self-reported health. The EQ-5D-3L
Score is calculated using dimensions from the questionnaire and high scores indicating better self-reported
health. The number of completed questionnaires is shown above each column (Data Supplement for more
details). BCG, Bacillus Calmette-Guerin; RC, radical cystectomy.
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FIG 3. Bladder cancer-specific EORTC
PROMs questionnaire outcomes. Scores
range from 0 to 100. A high score for uri-
nary symptoms, future worries, and ab-
dominal bloating and flatulence represents
a high level of symptomatology. A high
score for sexual functioning represents a
high level of functioning. For individual
items (malaise, intravesical treatment is-
sues and risk of contaminating partner,
body image scale, and urostomy problems),
a high score is interpreted as worse.
Merged scores are generated from the
matching scales from either questionnaire
and presented together. The number of
completed questionnaires is shown above
each column (Data Supplement for more
details). BCG, Bacillus Calmette-Guerin;
RC, radical cystectomy.
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similar rates of screening between networks, and that many
patients (62.7%) had preference by the time they were
approached regarding BRAVO. Rates of preference were
similar between networks, suggesting that failure to recruit
was multifactorial. Treatment acceptance was high (43/50,
86%) and comparable to other surgical versus nonsurgical
trials (eg, 78% in ProtecT24). Fewer patients accepted RC
than BCG, likely reflecting its irreversibility and greater
physical impact.
Our data reveal important insights into the disease and
challenge preconceptions. First, BCG is often the default
first-line treatment because clinicians feel patients are
unfit for RC.25,26 We found that although 2/3 of screened
patients were . 70 years old and 3/4 had a smoking
history, most (around 80% of the total considered pop-
ulation) were judged fit for either treatment by urological
and anesthetic staff. Second, clinicians often manage
HRNMIBC as a nonlethal disease. We found that most
new high-grade NMI cancers were of high progression risk
(as defined by the presence of one or more adverse
prognostic risk factors). In the participants randomly
assigned to RC, 2/20 (10.0%) had muscle invasive BCs
and one had Gleason 4 1 3 5 7 T3a prostate cancer
in their final histology. These patients had received re-
resection and cross-sectional imaging,17 were reviewed
by a multidisciplinary meeting, and had seen specialist
uro-oncologists. In the BCG arm, two participants de-
veloped BC metastases during study follow-up (total
2/23 with metastatic BC). Thus, 10% of patients with new
HRNMIBC have a potentially lethal disease. Our findings
reflect nonrandomly assigned population-based observa-
tions suggesting a 14% difference in BC-specific survival
between BCG and immediate RC at 10 years, that met-
astatic BC is present in cystectomy specimens in around
5% of cases, and long-term cancer-specific survival rates
of around 90% with immediate RC.11,27,28 Finally, patients
fear RC as they perceive a low HRQOL. Few data support
this fear. Our HRQOL analysis was limited as not all pa-
tients were followed up for 12 months; however, some trends
in changes were noted over time. Specifically, within the
first 3 months, HRQOL may be superior with mBCG to RC,
but differences may disappear by 12 months. Conversely,
at 12 months, there was slightly more decision regret and
slightly lower emotional function scores in the BCG cohort,
suggesting ongoing concerns about uncertainty in BC
outcomes. These data support population-based surveys
regarding HRQOL in patients with the BC spectrum9,10 and
clinical trial data measuring recovery13 after RC.
Although these findings may suggest that RC has superior
oncological outcomes with limited impact of HRQOL, our
data do not support RC as the standard of care for all
patients. The study was designed to test the feasibility of
a larger trial, and so findings with respect to UCC outcomes
or impact of HRQOL are underpowered and need to be
interpreted cautiously. In the RC cohort, 25% of patients
had no tumor in their cystectomy specimen (suggesting
possible overtreatment) and only 10% had invasive cancer.
Although longer-term outcomes of the 65% with NMI are
unknown, it is likely that many would not develop pro-
gressive disease and would not need RC. In keeping with
this, most patients in the BCG arm kept their bladders
in situ and there was little change in their HRQOL during
treatment. Although HRQOL and decision regret in the
mBCG cohort may change with longer follow-up, at closure,
there were no major differences between each arm. As
such, we suggest our findings be used to inform patients
about the relative risks of each approach, and recommend
use of an individualized risk-adaptive approach.
AFFILIATIONS
1Academic Urology Unit, University of Sheffield, Sheffield, United
Kingdom
2Clinical Trials Research Unit, Leeds Institute for Clinical Trials
Research, University of Leeds, Leeds, United Kingdom
3Institute of Clinical and Applied Health Research, University of Hull,
Hull, United Kingdom
4Freeman Hospital, Newcastle, United Kingdom
5St James’s University Hospital, Leeds, United Kingdom
6Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United
Kingdom
7Hull and East Yorkshire NHS Trust, Hull, United Kingdom
8Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom
9Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford,
United Kingdom
10Airedale NHS Foundation Trust, Keighley, United Kingdom
11Department of Urology, Royal Hallamshire Hospital, Sheffield, United
Kingdom
CORRESPONDING AUTHOR
James W. F. Catto, MBChB, PhD, Academic Urology Unit, G Floor, The
Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10
2RX, United Kingdom; e-mail: j.catto@sheffield.ac.uk.
STUDY GROUPS
BRAVO study group members: Zahir Abbasi, Linzi Bone, Angela
Brocklehurst, Nicolas Bryan, Lindsay Caygill, Jeremy Crew, Russsell
Dowde, Jan Farrell, Jonathan Gill, Lisa Gledhill, Fredddie Hamdy, Susan
Hill, Helen Hothersall, Anne Kay, Phil Kelly, Bernadette Kilbane, Sanjeev
Kotwal, Kate Linton, Stephen Littler, Tiago Mendonca, Suzanne Miles,
Stephen Mitchell, Peter Murphy, Vicky Murray, Naledi Mzwimbi, Alan
Paul, Ramanan Rajasundaram, Julie Rawlings, Hannah Roberts, Helen
Robertshaw, Wendy Robson, Derek Rosario, Kully Sandhu, Paul Sagar,
Alison Shaw, Rajindrah Singh, Nick Smith, Tina Soar, Zoe Storton,
Beverley Taylor, Francis Thomas, Nicky Thomas, Suresh Venugopal,
Rachel Walker, Louise Weatherley, and Susan Wormley.
DISCLAIMER
J.W.F.C. has received reimbursement for consultancy from Astra Zeneca,
Roche, and Janssen, speaker fees from BMS, MSD, Nucleix, and Roche,
and honoraria for membership of an advisory board for Ferring. J.W.F.C. is
funded by an NIHR Research Professorship. The remaining authors
declare no potential conflicts of interest.
CLINICAL TRIAL INFORMATION
ISRCTN12509361 Registered 06/09/16.
Journal of Clinical Oncology 11
Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer
Downloaded from ascopubs.org by 176.253.25.198 on December 18, 2020 from 176.253.025.198
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
Disclosures provided by the authors are available with this article at DOI
https://doi.org/10.1200/JCO.20.01665.
AUTHOR CONTRIBUTIONS
Conception and design: James W. F. Catto, Michelle Collinson, Heather
Poad, Maureen Twiddy, Mark Johnson, Rohit Chahal, Matt Simms,
Phillip Koenig, Julia M. Brown
Financial support: James W. F. Catto
Administrative support: James W. F. Catto, Kathryn Gordon
Provision of study materials or patients: James W. F. Catto, Kathryn
Gordon, Rohit Chahal, Matt Simms, Richard Bell, Phillip Koenig, Louise
Goodwin
Collection and assembly of data: James W. F. Catto, Kathryn Gordon,
Michelle Collinson, Heather Poad, Mark Johnson, Sunjay Jain, Rohit
Chahal, Mohantha Dooldeniya, Richard Bell, Phillip Koenig, Samantha
Conroy, Louise Goodwin, Aidan P. Noon, Julie Croft, Julia M. Brown
Data analysis and interpretation: James W. F. Catto, Michelle Collinson,
Maureen Twiddy, Rohit Chahal, Phillip Koenig, Julie Croft, Julia M.
Brown
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
ACKNOWLEDGMENT
We gratefully acknowledge the ongoing support of participants, principal
investigators, research nurses, MDT coordinators, data managers, and
other site staff who have been responsible for setting up, recruiting
participants, and collecting the data for the study. This study was funded
by Yorkshire Cancer Research (Study S388). The funder had no role in
the design, analysis, or collection of the data; in writing the manuscript;
or in the decision to submit the manuscript for publication. We are
grateful for the study oversight provided by the sponsor Sheffield
Teaching Hospitals NHS Trust and themembers of the TSC. We thank the
Independent steering group members: Alison Birtle (Chair), Simon
Fulford, and Chris Metcalfe.
REFERENCES
1. Cumberbatch MGK, Jubber I, Black PC, et al: Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur Urol
74:784-795, 2018
2. Leal J, Luengo-Fernandez R, Sullivan R, et al: Economic burden of bladder cancer across the European Union. Eur Urol 69:438-447, 2016
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using
EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466-475, 2006; discussion 475-477
4. Thomas F, Noon AP, Rubin N, et al: Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol 63:
145-154, 2013
5. Babjuk M, Burger M, Comperat EM, et al: European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)—
2019 update. Eur Urol 76:639-657, 2019
6. Malmstrom PU, Sylvester RJ, Crawford DE, et al: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing
intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247-256, 2009
7. Edmondson AJ, Birtwistle JC, Catto JWF, et al: The patients’ experience of a bladder cancer diagnosis: A systematic review of the qualitative evidence. J Cancer
Surviv 11:453-461, 2017
8. Pang KH, Groves R, Venugopal S, et al: Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy. Eur Urol 73:363-371,
2018
9. Mason SJ, Downing A, Wright P, et al: Health-related quality of life after treatment for bladder cancer in England. Br J Cancer 118:1518-1528, 2018
10. Hardt J, Filipas D, Hohenfellner R, et al: Quality of life in patients with bladder carcinoma after cystectomy: First results of a prospective study. Qual Life Res 9:
1-12, 2000
11. Klaassen Z, Kamat AM, Kassouf W, et al: Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: New insights and updated
recommendations. Eur Urol 74:597-608, 2018
12. Paramasivan S, Huddart R, Hall E, et al: Key issues in recruitment to randomised controlled trials with very different interventions: A qualitative investigation of
recruitment to the SPARE trial (CRUK/07/011). Trials 12:78, 2011
13. Catto JWF, Khetrapal P, Ambler G, et al: Multidomain quantitative recovery following radical cystectomy for patients within the robot-assisted radical
cystectomy with intracorporeal urinary diversion versus open radical cystectomy randomised controlled trial: The first 30 patients. Eur Urol 74:531-534,
2018
14. Oughton JB, Poad H, TwiddyM, et al: Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder
cancer (BRAVO): A protocol for a randomised controlled feasibility study. BMJ Open 7:e017913, 2017
15. Eble JN, Sauter G, Epstein JI, et al: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male
Genital Organs. Lyon, France, IARC Press, 2004
16. Histological Typing of Urinary Bladder Tumours. Geneva, Switzerland, World Health Organization, 1973
17. Cumberbatch MGK, Foerster B, Catto JWF, et al: Repeat transurethral resection in non-muscle-invasive bladder cancer: A systematic review. Eur Urol 73:
925-933, 2018
18. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional
cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 163:1124-1129, 2000
19. Konety BR, Dhawan V, Allareddy V, et al: Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: Data from the health care
utilization project. J Urol 173:1695-1700, 2005
20. Boustead GB, Fowler S, Swamy R, et al: Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons
(BAUS) urological tumour registry. BJU Int 113:924-930, 2014
21. Rabin R, de Charro F: EQ-5D: A measure of health status from the EuroQol Group. Ann Med 33:337-343, 2001
22. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in
international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
12 © 2020 by American Society of Clinical Oncology
Catto et al
Downloaded from ascopubs.org by 176.253.25.198 on December 18, 2020 from 176.253.025.198
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
23. Elliott D, Husbands S, Hamdy FC, et al: Understanding and improving recruitment to randomised controlled trials: Qualitative research approaches. Eur Urol 72:
789-798, 2017
24. Hamdy FC, Donovan JL, Lane JA, et al: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415-1424,
2016
25. Goossens-Laan CA, Leliveld AM, Verhoeven RH, et al: Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer.
Int J Cancer 135:905-912, 2014
26. Noon AP, Albertsen PC, Thomas F, et al: Competing mortality in patients diagnosed with bladder cancer: Evidence of undertreatment in the elderly and female
patients. Br J Cancer 108:1534-1540, 2013
27. Gontero P, Sylvester R, Pisano F, et al: Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus
Calmette-Guerin: Results of a retrospective multicenter study of 2451 patients. Eur Urol 67:74-82, 2015
28. Hautmann RE, Volkmer BG, Gust K: Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer
(T1 G3). World J Urol 27:347-351, 2009
29. Cumberbatch MG, Cox A, Teare D, et al: Contemporary occupational carcinogen exposure and bladder cancer: A systematic review and meta-analysis. JAMA
Oncol 1:1282-1290, 2015
30. Reed O, Jubber I, Griffin J, et al: Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer
phenotypes. PLoS One 15:e0239338, 2020
n n n
Journal of Clinical Oncology 13
Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer
Downloaded from ascopubs.org by 176.253.25.198 on December 18, 2020 from 176.253.025.198
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled
BRAVO-Feasibility Study
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted.
Relationships are self-held unless noted. I5 Immediate Family Member, Inst5My Institution. Relationships may not relate to the subject matter of this manuscript.
For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
James W. F. Catto
Honoraria: Abbott Laboratories
Consulting or Advisory Role: AstraZeneca/MedImmune, Janssen, Ferring
Speakers’ Bureau: ASCO, Roche, AstraZeneca/MedImmune, MSD Oncology,
Nucleix
Travel, Accommodations, Expenses: eau
Mark Johnson




No other potential conflicts of interest were reported.
© 2020 by American Society of Clinical Oncology
Catto et al
Downloaded from ascopubs.org by 176.253.25.198 on December 18, 2020 from 176.253.025.198
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
